

Financial Tear Sheet

Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the high-value drug profiling and therapeutic tissues markets

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations &
 Corporate
 Communications
Phone: 858-224-1092
Email:
 skunszabo@organovo.com

 [2017 Annual Report](#)  [Investor Presentation](#)

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.10
Change (%)	▲ 0.02 (1.85%)
Volume	920,000
52 Week Low	\$0.93
Market Cap	\$121,919,570
Rolling EPS	-0.36
PE Ratio	0
Shares Outstanding	110,835,973
Data as of 03/16/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

03/15/18

Organovo to Present at H.C. Wainwright Nash Investor Conference

03/08/18

Organovo to Present at 30th Annual ROTH Conference

02/08/18

Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 Outlook

Date	Title
03/19/18 2:40 p.m. ET	Organovo Holdings Inc at the H.C. Wainwright NASH Investor Conference

SEC Filings

Filing Date	Form
03/16/18	POS AM
03/16/18	424B5
03/16/18	8-K
02/22/18	EFFECT

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager